[1]
|
Walsh, D.M. and Selkoe, D.J. (2004) Deciphering the Molecular Basis of Memory Failure in Alzheimer’s Disease. Neuron, 44, 181-193. http://dx.doi.org/10.1016/j.neuron.2004.09.010
|
[2]
|
Heneka, M.T. and O’Banion. M.K. (2007) Inflammatory Processes in Alzheimer’s Disease. Journal of Neuroimmunology, 184, 69-91. http://dx.doi.org/10.1016/j.jneuroim.2006.11.017
|
[3]
|
Lee, V.M., Goedert, M. and Trojanowski, J.Q. (2001) Neurodegenerative Tauopathies. Annual Review of Neuroscience, 24, 1121-1159. http://dx.doi.org/10.1146/annurev.neuro.24.1.1121
|
[4]
|
Sue, W. and Griffin, T. (2006) Inflammation and Neurodegenerative Diseases. The American Journal of Clinical Nutrition, 83, 470S-474S.
|
[5]
|
Jackson, S., Ham, R.J. and Wilkinson, D. (2004) The Safety and Tolerability of Donepezil in Patients with Alzheimer’s Disease. British Journal of Clinical Pharmacology, 58, 1-8. http://dx.doi.org/10.1111/j.1365-2125.2004.01848.x
|
[6]
|
Kumar, V., Anand, R., Messina, J., Hartman, R. and Veach, J. (2000) An Efficacy and Safety Analysis of Exelon® in Alzheimer’s Disease Patients with Concurrent Vascular Risk Factors. European Journal of Neurology, 7, 159-169. http://dx.doi.org/10.1046/j.1468-1331.2000.00046.x
|
[7]
|
Petersen, R.C., et al. (2005) Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. New England Journal of Medicine, 352, 2379-2388. http://dx.doi.org/10.1056/NEJMoa050151
|
[8]
|
Salloway, S., et al. (2004) Efficacy of Donepezil in Mild Cognitive Impairment A Randomized Placebo-Controlled Trial. Neurology, 63, 651-657. http://dx.doi.org/10.1212/01.WNL.0000134664.80320.92
|
[9]
|
Corey-Bloom, J., Anand, R. and Veach, J.F. (1998) A Randomized Trial Evaluating the Efficacy and Safety of ENA 713(Rivastigmine Tartrate), a New Acetylcholinesterase Inhibitor, in Patients with Mild to Moderately Severe Alzheimer’s Disease. International Journal of Geriatric Psychopharmacology, 1, 55-65.
|
[10]
|
Bai, D. (2007) Development of Huperzine A and B for Treatment of Alzheimer’s Disease. Pure and Applied Chemistry, 79, 469-479. http://dx.doi.org/10.1351/pac200779040469
|
[11]
|
Camps, P., et al. (2008) Novel Donepezil-Based Inhibitors of Acetyl-And Butyrylcholinesterase and Acetylcholinesterase-Induced β-Amyloid Aggregation. Journal of Medicinal Chemistry, 51, 3588-3598. http://dx.doi.org/10.1021/jm8001313
|
[12]
|
Sahu, S.K., Gummadi, S.N., Manoj, N. and Aradhyam, G.K. (2007) Phospholipid Scramblases: An Overview. Archives of Biochemistry and Biophysics, 462, 103-114. http://dx.doi.org/10.1016/j.abb.2007.04.002
|
[13]
|
Simakova, O. and Arispe, N.J. (2007) The Cell-Selective Neurotoxicity of the Alzheimer’s Aβ Peptide Is Determined by Surface Phosphatidylserine and Cytosolic ATP Levels. Membrane Binding Is Required for Aβ Toxicity. The Journal of Neuroscience, 27, 13719-13729. http://dx.doi.org/10.1523/JNEUROSCI.3006-07.2007
|
[14]
|
Hensley, K., et al. (1994) A Model for Beta-Amyloid Aggregation and Neurotoxicity Based on Free Radical Generation by the Peptide: Relevance to Alzheimer Disease. Proceedings of the National Academy of Sciences, 91, 3270-3274. http://dx.doi.org/10.1073/pnas.91.8.3270
|
[15]
|
Huang, X., et al. (1999) The Aβ Peptide of Alzheimer’s Disease Directly Produces Hydrogen Peroxide through Metal ion Reduction. Biochemistry, 38, 7609-7616. http://dx.doi.org/10.1021/bi990438f
|
[16]
|
Dougherty, J.J., Wu, J. and Nichols, R.A. (2003) β-Amyloid Regulation of Presynaptic Nicotinic Receptors in Rat Hippocampus and Neocortex. The Journal of Neuroscience, 23, 6740-6747.
|
[17]
|
Emre, M., Mecocci, P. and Stender, K. (2008) Pooled Analyses on Cognitive Effects of Memantine in Patients with Moderate to Severe Alzheimer’s Disease. Journal of Alzheimer’s Disease, 14, 193-199.
|
[18]
|
Fritze, J. and Walden, J. (1994) Clinical Findings with Nimodipine in Dementia: Test of the Calcium Hypothesis. Journal of Neural Transmission. Supplementum, 46, 439-453.
|
[19]
|
Facchinetti, F., Fasolato, C., Giudice, E.D., Burgo, A., Furegato, S., et al. (2006) Nimodipine Selectively Stimulates β-Amyloid 1-42 Secretion by a Mechanism Independent of Calcium Influx Blockage. Neurobiology of Aging, 27, 218-227. http://dx.doi.org/10.1016/j.neurobiolaging.2005.02.006
|
[20]
|
Landreth, G., Jiang, Q., Mandrekar, S. and Heneka, M. (2008) PPARγ Agonists as Therapeutics for the Treatment of Alzheimer’s Disease. Neurotherapeutics, 5, 481-489. http://dx.doi.org/10.1016/j.nurt.2008.05.003
|
[21]
|
Abbott, M.A., Wells, D.G. and Fallon, J.R. (1999) The Insulin Receptor Tyrosine Kinase Substrate p58/53 and the Insulin Receptor Are Components of CNS Synapses. The Journal of Neuroscience, 19, 7300-7308.
|
[22]
|
Cole, A.R., Astell, A., Green, C. and Sutherland, C. (2007) Molecular Connexions between Dementia and Diabetes. Neuroscience & Biobehavioral Reviews, 31, 1046-1063. http://dx.doi.org/10.1016/j.neubiorev.2007.04.004
|
[23]
|
Orgogozo, J.M., Gilman, S., Dartigues, J.F., Laurent, B., Puel, M., et al. (2003) Subacute Meningoencephalitis in a Subset of Patients with AD after Abeta42 Immunization. Neurology, 61, 46-54. http://dx.doi.org/10.1212/01.WNL.0000073623.84147.A8
|
[24]
|
Winblad, B.G., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., et al. (2009) Results of the First-in-Man Study with the Active Aβ Immunotherapy CAD106 in Alzheimer Patients. Alzheimer’s & Dementia, 5, P113-P114. http://dx.doi.org/10.1016/j.jalz.2009.05.356
|
[25]
|
Rinne, J.O., Brooks, D.J., Rossor, M.N., Fox, N.C., Bullock, R., et al. (2010) 11C-PiB PET Assessment of Change in Fibrillar Amyloid-β Load in Patients with Alzheimer’s Disease Treated with Bapineuzumab: A Phase 2, Double-Blind, Placebo-Controlled, Ascending-Dose Study. The Lancet Neurology, 9, 363-372. http://dx.doi.org/10.1016/S1474-4422(10)70043-0
|
[26]
|
Seubert, P., Barbour, R., Khan, K., Motter, R., Tang, P., et al. (2008) Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse. Neurodegenerative Diseases, 5, 65-71. http://dx.doi.org/10.1159/000112834
|
[27]
|
Siemers, E.R., Friedrich, S., Dean, R.A., Gonzales, C.R., Farlow, M.R., Paul, S.M. and DeMattos, R.B. (2010) Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid [beta] after a Single Administration of an Amyloid [beta] Monoclonal Antibody in Subjects with Alzheimer Disease. Clinical Neuropharmacology, 33, 67-73. http://dx.doi.org/10.1097/WNF.0b013e3181cb577a
|
[28]
|
DaSilva, K.A., Brown, M.E., and McLaurin, J. (2009) Reduced Oligomeric and Vascular Amyloid-β Following Immunization of TgCRND8 Mice with an Alzheimer’s DNA Vaccine. Vaccine, 27, 1365-1376. http://dx.doi.org/10.1016/j.vaccine.2008.12.044
|
[29]
|
Himmler, A., Drechsel, D., Kirschner, M.W. and Martin, D.W. (1989) Tau Consists of a Set of Proteins with Repeated C-Terminal Microtubule-Binding Domains and Variable N-Terminal Domains. Molecular and Cellular Biology, 9, 1381-1388.
|
[30]
|
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. and Kivipelto, M. (2010) Alzheimer’s Disease: Clinical Trials and Drug Development. The Lancet Neurology, 9, 702-716. http://dx.doi.org/10.1016/S1474-4422(10)70119-8
|
[31]
|
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., et al. (2005) Inhibition of Glycogen Synthase Kinase-3 by Lithium Correlates with Reduced Tauopathy and Degeneration in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 102, 6990-6995. http://dx.doi.org/10.1073/pnas.0500466102
|
[32]
|
Wischik, C.M., Edwards, P.C., Lai, R.Y., Roth, M. and Harrington, C.R. (1996) Selective Inhibition of Alzheimer Disease-Like Tau Aggregation by Phenothiazines. Proceedings of the National Academy of Sciences of the United States of America, 93, 11213-11218. http://dx.doi.org/10.1073/pnas.93.20.11213
|
[33]
|
Deiana, S., Harrington, C.R., Wischik, C.M. and Riedel, G. (2009) Methylthioninium Chloride Reverses Cognitive Deficits Induced by Scopolamine: Comparison with Rivastigmine. Psychopharmacology, 202, 53-65. http://dx.doi.org/10.1007/s00213-008-1394-2
|
[34]
|
Wischik, C. (2009) Rember: Issues in Design of a Phase 3 Disease Modifying Clinical Trial of Tau Aggregation Inhibitor Therapy in Alzheimer’s Disease. Alzheimer’s & Dementia, 5, P74. http://dx.doi.org/10.1016/j.jalz.2009.05.175
|
[35]
|
Nogales, E., Wolf, S.G., Khan, I.A., Ludueña, R.F. and Downing, K.H. (1995) Structure of Tubulin at 6.5 Å and Location of the Taxol-Binding Site. Nature, 375, 424-427. http://www.nature.com/nature/journal/v375/n6530/pdf/375424a0.pdf
|
[36]
|
Amos, L.A. and Lö we, J. (1999) How Taxol® Stabilises Microtubule Structure. Chemistry & Biology, 6, R65-R69. http://dx.doi.org/10.1016/S1074-5521(99)89002-4
|
[37]
|
Shemesh, O.A. and Spira, M.E. (2011) Rescue of Neurons from Undergoing Hallmark Tau-Induced Alzheimer’s Disease Cell Pathologies by the Antimitotic Drug Paclitaxel. Neurobiology of Disease, 43, 163-175. http://dx.doi.org/10.1016/j.nbd.2011.03.008
|
[38]
|
Das, V. and Miller, J.H. (2012) Microtubule Stabilization by Peloruside A and Paclitaxel Rescues Degenerating Neurons from Okadaic Acid-Induced Tau Phosphorylation. European Journal of Neuroscience, 35, 1705-1717. http://dx.doi.org/10.1111/j.1460-9568.2012.08084.x
|
[39]
|
Michaelis, M.L., Ranciat, N., Chen, Y., Bechtel, M., Ragan, R., et al. (1998) Protection against Beta-Amyloid Toxicity in Primary Neurons by Paclitaxel (Taxol). Journal of Neurochemistry, 70, 1623-1627. http://dx.doi.org/10.1046/j.1471-4159.1998.70041623.x
|
[40]
|
Michaelis, M.L., Chen, Y., Hill, S., Reiff, E., Georg, G., Rice, A. and Audus, K. (2002) Amyloid Peptide Toxicity and Microtubule-Stabilizing Drugs. Journal of Molecular Neuroscience, 19, 101-105. http://dx.doi.org/10.1007/s12031-002-0018-2
|
[41]
|
Michaelis, M.L., Ansar, S., Chen, Y., Reiff, E.R., Seyb, K.I., et al. (2005) β-Amyloid-Induced Neurodegeneration and Protection by Structurally Diverse Microtubule-Stabilizing Agents. Journal of Pharmacology and Experimental Therapeutics, 312, 659-668. http://dx.doi.org/10.1124/jpet.104.074450
|
[42]
|
Brunden, K.R., Yao, Y., Potuzak, J.S., Ferrer, N.I., Ballatore, C., et al. (2011) The Characterization of Microtubule- Stabilizing Drugs as Possible Therapeutic Agents for Alzheimer’s Disease and Related Tauopathies. Pharmacological Research, 63, 341-351. http://dx.doi.org/10.1016/j.phrs.2010.12.002
|
[43]
|
Hoffmann, J., Fichtner, I., Lemm, M., Lienau, P., Hess-Stumpp, H., et al. (2009) Sagopilone Crosses the Blood-Brain Barrier in Vivo to Inhibit Brain Tumor Growth and Metastases. Neuro-Oncology, 11, 158-166. http://dx.doi.org/10.1215/15228517-2008-072
|
[44]
|
O’Reilly, T., Wartmann, M., Brueggen, J., Allegrini, P.R., Floersheimer, A., Maira, M. and McSheehy, P.M. (2008) Pharmacokinetic Profile of the Microtubule Stabilizer Patupilone in Tumor-Bearing Rodents and Comparison of Anti-Cancer Activity with Other MTS in Vitro and in Vivo. Cancer Chemotherapy and Pharmacology, 62, 1045-1054. http://dx.doi.org/10.1007/s00280-008-0695-9
|
[45]
|
Ballatore, C., Brunden, K.R., Huryn, D.M., Trojanowski, J.Q., Lee, V.M.Y. and Smith III, A.B. (2012) Microtubule Stabilizing Agents as Potential Treatment for Alzheimer’s Disease and Related Neurodegenerative Tauopathies. Journal of Medicinal Chemistry, 55, 8979-8996. http://dx.doi.org/10.1021/jm301079z
|
[46]
|
Barten, D.M., Fanara, P., Andorfer, C., Hoque, N., Wong, P.Y.A., et al. (2012) Hyperdynamic Microtubules, Cognitive Deficits, and Pathology Are Improved in Tau Transgenic Mice with Low Doses of the Microtubule-Stabilizing Agent BMS-241027. The Journal of Neuroscience, 32, 7137-7145. http://dx.doi.org/10.1523/JNEUROSCI.0188-12.2012
|
[47]
|
Hao, L., Zhang, Q., Yu, T., Yu, L. and Cheng, Y. (2011) Modulation of Ultra-Low-Molecular-Weight Heparin on [Ca2+]i in Nervous Cells. Brain Research Bulletin, 86, 355-359. http://dx.doi.org/10.1016/j.brainresbull.2011.08.018
|
[48]
|
Vellas, B., Sol, O., Snyder, P.J., Ousset, P.J., Haddad, R., et al. (2011) EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo-Controlled, Double-Blind Study. Current Alzheimer Research, 8, 203-212. http://dx.doi.org/10.2174/156720511795256053
|
[49]
|
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. and Kivipelto, M. (2010) Alzheimer’s Disease: Clinical Trials and Drug Development. The Lancet Neurology, 9, 702-716. http://dx.doi.org/10.1016/S1474-4422(10)70119-8
|
[50]
|
Winblad, B., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., et al. (2012) Safety, Tolerability, and Antibody Response of Active Aβ Immunotherapy with CAD106 in Patients with Alzheimer’s Disease: Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study. The Lancet Neurology, 11, 597-604. http://dx.doi.org/10.1016/S1474-4422(12)70140-0
|
[51]
|
Scheltens, P., Sperling, R., Salloway, S. and Fox, N. (2012) Bapineuzumab IV Phase 3 Results. 5th Conference Clinical Trials on Alzheimer’s Disease. The Journal of Nutrition, Health & Aging, 16, 795-872.
|
[52]
|
Doody, R. (2012) Safety and Efficacy of Solanezumab in Patient with Mild to Moderate Alzheimer’s Disease: Results from Phase 3. 5th Conference Clinical Trials on Alzheimer’s Disease. The Journal of Nutrition, Health & Aging, 16, 801-802.
|
[53]
|
Hampel, H., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., et al. (2009) Lithium Trial in Alzheimer’s Disease: A Randomized, Single-Blind, Placebo-Controlled, Multicenter 10-Week Study. The Journal of Clinical Psychiatry, 70, 922-931. http://dx.doi.org/10.4088/JCP.08m04606
|
[54]
|
Wischik, C.M., Bentham, P., Wischik, D.J. and Seng, K.M. (2008) O3-04-07: Tau Aggregation Inhibitor (TAI) Therapy with RemberTM Arrests Disease Progression in Mild and Moderate Alzheimer’s Disease over 50 Weeks. Alzheimer’s & Dementia, 4, T167. http://dx.doi.org/10.1016/j.jalz.2008.05.438
|
[55]
|
Zhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., et al. (2005) Microtubule-Binding Drugs Offset Tau Sequestration by Stabilizing Microtubules and Reversing Fast Axonal Transport Deficits in a Tauopathy Model. Proceedings of the National Academy of Sciences of the United States of America, 102, 227-231. http://dx.doi.org/10.1073/pnas.0406361102
|
[56]
|
Texel, S.J. and Mattson, M.P. (2011) Impaired Adaptive Cellular Responses to Oxidative Stress and the Pathogenesis of Alzheimer’s Disease. Antioxidants & Redox Signaling, 14, 1519-1534. http://dx.doi.org/10.1089/ars.2010.3569
|